Core Viewpoint - The company, Haijia Medical, announced a share buyback program due to its stock price not reflecting its intrinsic value or business prospects, committing to repurchase shares for at least RMB 300 million [1]. Group 1: Share Buyback Announcement - On December 15, Haijia Medical disclosed its intention to buy back shares, stating that the current trading price does not reflect its intrinsic value [1]. - The company executed its first buyback on December 17, purchasing approximately 493,800 shares for about HKD 6.0098 million [1]. Group 2: Market Performance Analysis - On December 12, Haijia Medical's stock hit a year-low of HKD 11.33, indicating a downward trend away from the 5-day moving average [3]. - Since August 1, the stock has been in a downtrend, with a significant drop following a profit warning, leading to low trading volumes [3][5]. - The stock's highest price on December 12 was HKD 11.61, which was below the lower Bollinger Band of HKD 11.64, indicating an oversold condition [3]. Group 3: Trading Volume and Market Sentiment - Following the buyback announcement, trading volume increased significantly, with a notable rise in daily average volume, indicating a shift in market sentiment [5][8]. - On December 16, the stock rose by 3.27% but showed signs of selling pressure, with trading volume increasing by 152.05% compared to the previous day [5][6]. Group 4: Financial Performance and Valuation - Haijia Medical's mid-year report indicated a decline in revenue for inpatient and outpatient services, with inpatient revenue at RMB 1.22 billion (down 18.4% year-on-year) and outpatient revenue at RMB 722 million (down 11.2% year-on-year) [9]. - The company reported stable patient visits at 2.2 million, suggesting demand for its services remains unaffected despite revenue declines [9]. - The company is optimizing capital allocation, with a decrease in capital expenditures to RMB 242 million, down 28.5% year-on-year, and plans to focus on acquisitions rather than new hospital constructions [10]. Group 5: Industry Valuation Context - Haijia Medical's price-to-earnings (PE) ratio stands at 15.71, significantly lower than the industry average of 17, indicating a potential undervaluation compared to peers [11].

Group 1 - The core point of the article is that Haijia Medical (06078.HK) has seen a significant increase in its stock price, rising over 4% and currently trading at 12.6 HKD with a transaction volume of 40.78 million HKD [1]

Group 1 - The core viewpoint of the article highlights that Haijia Medical (06078) has seen a stock price increase of over 4%, currently trading at 12.6 HKD with a transaction volume of 40.78 million HKD [1] - Haijia Medical announced a share buyback of approximately 6.0098 million HKD for 493,800 shares on December 17 [1] - The company plans to utilize its buyback authorization to repurchase shares in the open market for a total price of no less than 300 million RMB [1] Group 2 - According to CMB International, the pressure on cost control is easing, and the elimination of outdated production capacity is expected to allow private medical institutions to return to a faster growth trajectory [1] - CMB International recommends high-quality stocks like Haijia Medical, which are expected to see a rebound in short-term performance and have a clear long-term expansion path [1]

Group 1 - The core viewpoint of the article highlights that Haijia Medical (06078) has seen a stock price increase of over 4%, currently trading at 12.6 HKD with a transaction volume of 40.78 million HKD [1] - Haijia Medical announced a share buyback of approximately 6.0098 million HKD for 493,800 shares, indicating a strategic move to enhance shareholder value [1] - The company plans to utilize its buyback authorization to repurchase shares in the open market for a total price of no less than 300 million RMB [1] Group 2 - According to CMB International, the pressure on cost control is easing, and the elimination of outdated production capacity is expected to allow private medical institutions to return to a faster growth trajectory [1] - CMB International recommends high-quality stocks like Haijia Medical, which are expected to see a rebound in short-term performance and have a clear long-term expansion path [1]

Group 1 - The company, Haijia Medical (06078), announced a share buyback plan to repurchase approximately 493,800 shares at a cost of about HKD 6.0098 million on December 17, 2025 [1]

Group 1 - The company, Haijia Medical (06078.HK), announced a share buyback on December 17, 2023, spending HKD 6.01 million to repurchase 494,000 shares [1]

Group 1 - The company, Haijia Medical (06078), announced a share buyback plan, intending to repurchase approximately 493,800 shares at a cost of about HKD 6.0098 million [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 海吉亞醫療控股有限公司 呈交日期： 2025年12月17日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06078 | 說明 | 普通股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | ...

Group 1 - The core viewpoint of the article is that Haijia Medical (6078.HK) believes its current share price does not reflect its intrinsic value or actual business prospects, prompting the company to initiate a share buyback program [1] - Haijia Medical's share price initially rose over 6%, currently trading at 12 HKD, with a total market capitalization of 7.45 billion HKD [1] - The company plans to utilize its buyback authorization to repurchase shares in the open market for a total price of no less than 300 million RMB [1] Group 2 - The company aims to continuously optimize shareholder returns based on market conditions, focusing on efficient capital allocation through buybacks, dividends, and merger expansions [1]

海吉亚医疗(6078.HK)盘初一度涨超6%，现报12港元，总市值74.5亿港元。消息上，海吉亚医疗昨日盘 后公告，公司认为股份目前的交易价格并未反映其内在价值或公司的实际业务前景。因此，公司董事会 已议决利用购回授权，以不时在公开市场上按不少于人民币300百万元的总价格购回股份。未来，公司 还将视市场情况，持续优化股东回报，在回购、分红及并购扩张中做出更高效的、更有利于股东价值的 资本配置安排。 ...